alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
COVID-19 Vaccine Safety Technical (VaST) 

Subgroup

Grace M. Lee, MD MPH

VaST Co-Chair

Advisory Committee on Immunization Practices

January 27, 2021

Introduction 
COVID-19 Vaccine Safety Technical (VaST) Subgroup

Objectives

 Review, evaluate, and interpret post-authorization/approval 

COVID-19 vaccine safety data

 Serve as the central hub for technical subject matter expertise 

from federal agencies conducting post-authorization/approval 

safety monitoring

 Advise on analyses, interpretation, and data presentation

 Provide updates to the ACIP COVID-19 Vaccines Working Group 

and the ACIP on COVID-19 vaccine safety

2
COVID-19 Vaccine Safety Technical (VaST) Subgroup

 Ensure independence, transparency, and public accountability

 Composition

–

–

–

–

Co-chairs: Grace Lee (ACIP) and Bob Hopkins (NVAC)

Members: ACIP and NVAC representation independent expert 

consultants

2 CDC co-leads

8 ACIP ex officio members (FDA, NIH, OIDP, CMS, HRSA, IHS) and 

liaisons (VA , DoD)

3
VaST Activities

Pre-authorization

Jun – Oct 2020

• 10 meetings to prepare 

for vaccine safety 

surveillance

Nov – mid Dec 2020

• Transition to Vaccine 

Safety Data Review Group

• 4 meetings to review 

methods for vaccine 

safety monitoring and to 

finalize VaST procedures

ACIP 

Recommendations

Dec 12

• ACIP vote for 

Pfizer/ 

BioNTech

Dec 14

• 1st dose 

administered 

on in the U.S.

Dec 19

• ACIP vote for 

Moderna

Post-authorization

Dec 21

• First call to review safety 

data, one week after the 

start of vaccine 

administration in the U.S.

Dec 21 – present

• 6 meetings to date to 

review post-authorization 

data
safety monitoring timeline

start 

of vax

7

active surveillance, passive

surveillance, case consults
VaST Procedures 

 Data - Weekly review of available data on vaccine administration 

and adverse events of special interest (AESI)

 Shared learning - All members, federal partners, and subject 

matter experts are present for presentation of data

 Independence – VaST members discuss findings independently

 Reports – Summary and interpretation of aggregate data 

provided to the ACIP Secretariat on a regular basis 

9
Outline of Today’s Session

 COVID-19 vaccine safety update

 COVID-19 Vaccine Safety Technical (VaST) Subgroup discussion 

and interpretation

10
VaST Members 

Co-Chairs

Grace Lee (ACIP)

Robert Hopkins (NVAC)

ACIP Members

Beth Bell

Matt Daley

Veronica McNally

Kiepp Talbot

Expert Consultants

Kathy Edwards

Lisa Jackson

Martin Kulldorff

Laura Riley

Robert Schechter

Patricia Whitley-Williams

CDC Co-Leads

Lauri Markowitz

Melinda Wharton

Ex Officio and Liaison Representatives 

Tatiana Beresnev (NIH)

Steven Anderson; Karen Farizo; Richard Forshee; 

Narayan Nair; Hui Lee Wong (FDA)

Judith Steinberg (OIDP)

Jeffrey Kelman (CMS)

Matthew Clark (IHS)

Mary Rubin (HRSA)

Fran Cunningham (VA)

Limone Collins (DoD)

Administrative Support

Susan Hiers

Jared Woo

11 11
Exhibit 32.1
 
 
 Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as Adopted
 Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 Pursuant
    to 18 U. S. C. Section 1350, I, Arnold S. Lippa, hereby certify that, to the best of my knowledge, the Annual Report on Form 10-Q/A
    of DOV Pharmaceutical, Inc. for the quarter ended March 31, 2004 (the Report) fully complies with the requirements
    of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Report
    fairly presents, in all material respects, the financial condition and results of operations of DOV Pharmaceutical, Inc. A signed original
  of this written statement required by Section 906 has been provided to DOV and
  will be retained by DOV and furnished to the Securities and Exchange
  Commission or its staff upon request.
 
 /s/ Arnold S. Lippa
 Arnold S. Lippa
 Co-Chairman of the Board, Chief Executive Officer and President
 June
    28, 2004
 
 This certification
    accompanies this Report on Form 10-Q/A pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to
    the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of
    1934, as amended (the Exchange Act). Such certification will not be deemed to be incorporated by reference into any filing
    under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates
    it by reference.
Partnering for Vaccine Equity with 

National Organizations

National Partners Form a Powerful Network to Reduce Immunization Disparities and 

Increase Community-Level Engagement

Through the Partnering for Vaccine Equity program, CDC allocated $62.7M (fiscal year 21-22) to 

eight national organizations with longstanding ties with specific communities to enact sustainable 

change for communities of color experiencing immunization inequities.

Since 2021, these organizations have implemented vaccination activities, deployed educational 

campaigns, and equipped influential messengers in their local branches/affiliates to engage 

communities experiencing immunization inequities. To support these efforts, CDC provides national 

partners access to a learning community with other partners, data insights on key health and 

demographic data, and a repository of vaccine promotion and educational resources. 

National Organizations Engage Communities through Over 200 Local Affiliates

• Asian and Pacific Islander 

American Health Forum 

• Conference of National Black 

Churches 

• National Council of Negro Women

• National Alliance for Hispanic 

Health 

• National Minority Quality Forum 

• National Urban League 

• Northwest Portland Area Indian 

Health Board 

• UnidosUS 

Nationwide educational 

campaigns launched

Educational campaign 

languages and dialects, 

such as Arabic, Hawaiian, 

Indonesian, and Swahili

States reached through 

tailored educational 

campaigns, including 

Washington, D.C.

National Organizations are funded by CDC-RFA-IP21-2106

Program data represents data as of June 2022

https://www.cdc.gov/vaccines/health-equity/

Last updated 09/2022
<PAGE>

                                                                   Exhibit 23.2

                         INDEPENDENT AUDITORS' CONSENT


The Board of Directors
Westminster Capital, Inc:

We consent to incorporation by reference in the registration statement No. 
33-21177 on Form S-8 of Westminster Capital, Inc. of our report dated March 
1, 1997, relating to the consolidated statements of operations, comprehensive 
income, shareholders' equity, and cash flows of Westminster Capital, Inc. and 
subsidiaries for the year ended December 31, 1996, which report appears in 
the December 31, 1998, annual report on Form 10-K of Westminster Capital, Inc.


/s/ KPMG LLP

Los Angeles, California
April 5, 1999
No. 11-6961.

#### In re Lester Jon Ruston, Petitioner.

565 U.S. 1033, 132 S. Ct. 601,

181 L. Ed. 2d 443,

2011 U.S. LEXIS 8231.

November 14, 2011.

Motion of petitioner for leave to proceed in forma pau-peris denied, and petition for writ of mandamus dismissed. See Rule 39.8. As the petitioner has repeatedly abused this Court’s process, the Clerk is directed not to accept any further petition in noncriminal matters from petitioner unless the docketing fee required by Rule 38(a) is paid and the petition is submitted in compliance with Rule 33.1. See Martin v. District of Columbia Court of Appeals, 506 U.S. 1, 113 S. Ct. 397, 121 L. Ed. 2d 305 (1992) (per curiam). Justice Kagan took no part in the consideration or decision of this motion and this petition.
FIGURE 3. Percentage of private provider sites participating in a grantee

immunization information system-- United States, six cities§, and eight Territories†, 2006

No Report

0-33%

34-66%

67-94%

95-100%

Source: CY2006 IISAR

§Chicago, Illinois (0%-

33%); District of Columbia 

(67%–94%); Houston, 

Texas (0%–33%); New 

York City, New York 

(67%–94%); Philadelphia, 

Pennsylvania (67%–94%); 

San Antonio, Texas (67%–

94%).

National Coverage: 47% (excluding Territories)

†American Samoa, (No Report), 

Guam (No Report) , Marshall 

Islands (No Report), Federated 

States of Micronesia (No 

Report), N. Mariana Islands 

(67%-94%), Palau (No Report), 

Puerto Rico (0%-33%), Virgin 

Islands (67%-94%).
[Federal Register Volume 63, Number 134 (Tuesday, July 14, 1998)]
[Notices]
[Pages 37880-37881]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-18720]


-----------------------------------------------------------------------

FEDERAL EMERGENCY MANAGEMENT AGENCY

[FEMA-1229-DR]


West Virginia; Amendment No. 1 to Notice of a Major Disaster 
Declaration

AGENCY: Federal Emergency Management Agency (FEMA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice amends the notice of a major disaster for the 
State of West Virginia, (FEMA-1229-DR), dated July 1, 1998, and related 
determinations.

EFFECTIVE DATE: July 6, 1998.

FOR FURTHER INFORMATION CONTACT: Madge Dale, Response and Recovery 
Directorate, Federal Emergency Management Agency, Washington, DC 20472, 
(202) 646-3260.

SUPPLEMENTARY INFORMATION: The notice of a major disaster for the State 
of West

[[Page 37881]]

Virginia, is hereby amended to include Categories C through G under the 
Public Assistance program in the following areas among those areas 
determined to have been adversely affected by the catastrophe declared 
a major disaster by the President in his declaration of July 1, 1998:

    Braxton, Gilmer, Jackson, Kanawha, Roane and Wood Counties for 
Categories C through G under Public Assistance (already designated 
for Individual Assistance and Categories A and B under Public 
Assistance).
    Calhoun, Clay, Doddridge, Lewis, Marion, Pleasants, Ritchie, 
Tyler, and Wirt Counties for Individual Assistance and Public 
Assistance.
    Harrison, Marshall, Ohio, Webster, and Wetzel Counties for 
Public Assistance.

(The following Catalog of Federal Domestic Assistance Numbers (CFDA) 
are to be used for reporting and drawing funds: 83.537, Community 
Disaster Loans; 83.538, Cora Brown Fund Program; 83.539, Crisis 
Counseling; 83.540, Disaster Legal Services Program; 83.541, 
Disaster Unemployment Assistance (DUA); 83.542, Fire Suppression 
Assistance; 83.543, Individual and Family Grant (IFG) Program; 
83.544, Public Assistance Grants; 83.545, Disaster Housing Program; 
83.548, Hazard Mitigation Grant Program.)
Lacy E. Suiter,
Executive Associate Director, Response and Recovery Directorate.
[FR Doc. 98-18720 Filed 7-13-98; 8:45 am]
BILLING CODE 6718-02-P
EXHIBIT 32.02








CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO


18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002














In connection with the Quarterly Report of Morgan Stanley Smith Barney Spectrum Charter Graham L.P. (the “Partnership”) on Form10-Q for the quarter ended March 31, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Christian Angstadt, Chief Financial Officer of Demeter Management LLC, the general partner of the Partnership, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:




(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and




(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Partnership.




























By:
/s/ Christian AngstadtName:
Christian AngstadtTitle:
Chief Financial Officer ofDemeter Management LLC,General Partner of the registrantDate:
May 13, 2010
No. 11-5960.

#### Ron Joseph Meyers, Petitioner v. Minnesota.

565 U.S. 981, 132 S. Ct. 503,

181 L. Ed. 2d 354,

2011 U.S. LEXIS 7908.

October 31, 2011.

Petition for writ of certiorari to the Court of Appeals of Minnesota denied.
If there were a 

vaccine against 

cancer, wouldn’t 

you get it for 

your kids?

HPV vaccine is

cancer prevention. 

Talk to the doctor 

about vaccinating

your 11–12 year old

sons and daughters 

against HPV.

www.cdc.gov/vaccines/teens

CS249586-A

Distributed by:
ID Descriptor L* a* b* c h dL* da* db* dEcmc*

Standard 16-01 STANDARD 36.09 -4.50 5.10

Tolerance

1 1 FULL LIMIT 35.21 -4.52 5.11 -0.88 -0.02 0.01 0.49

2

3

4

5

6

7

8

9

Shade Number SAGE GREEN 1659 Piece/Roll Number 16-01

DLA/AIR FORCE SHADE TOLERANCE PROJECT July 14, 2017

Fabric Nomenclature NOMEX®/KEVLAR®/P-140, CLOTH, PLAIN 

AND BASKET WEAVE, ARAMID MIL-C-83429

COMMENTS: NUMBERS ARE FOR REFERENCE ONLY 

Equipment Type HUNTER ULTRA SCAN PRO Setting Mode: Specular Included - 

Reflectance

UV Filter – OUT UV Lamp 

OFF
DLA Customer Analysis Report & 

Engagement Summary

Instructions: Complete and submit request. All fields bordered in red are manditory, and dates entered must be YYYY-MM-DD 

formatted. 

For assistance in filling out a CRM Analytics Request, please send an Email to CRMAnalyitcs@dla.mil and an analyst will contact you.

Date of Request: Request by Date:

REQUESTER INFORMATION

First Name: Last Name:

Title: Grade/Rank:

Organization:

Phone: Email:

REQUESTER’S ROLE: Select the box which best represents your role.

DLA Senior Leader 

Warfighter Support Representative (WSR) / Customer Support Representative (CSR) 

Customer Facing Personnel 

Other (explain): ______________________________________________________________________

TYPE OF REPORT

PDF

This type of report is formal in nature and generally used in high level overviews. Delivered as a PDF it will include: cover sheet, a brief explanation 

of the analytic findings, geospatial maps identifying customer locations, the time frame the data covered, charts, tables, a glossary of terms, and DLA 

course of instruction that could be useful to the units identified in the report. This report does not allow for the recipient to cut and paste data elements 

and is intended to be a stand-alone report.

Spreadsheet

This type of report is generally used by a forward-facing customer advocate/trainer. It is delivered in the form of an Microsoft Excel spreadsheet and 

will include (but is not limited to); a glossary of terms; analytics; top 10-20 DODAAC’s using the CIC; top reasons units are contacting the CIC; most 

common NSNs; individual user POC Name, Email and phone number (when available), broken out by reasons for contact; and DLA tailored instruction 

that could be useful to the units identified in the report. Charts and graphs are able to be cut and pasted into different presentation media by the recipient 

of the report.

PowerPoint

This type of report is delivered in the form of a Microsoft Power Point (PPT) presentation and will be created using the standard DLA PPT presentation 

formats. The report elements will consist of those found in the PDF and/or spreadsheet reports listed above; bar charts, graphs, pie charts, maps and 

tables with trend analysis when practical.

Other

Possible examples:

- A report that would include a request for a specific geographic location, POC and contact information for a special training event where the person 

setting up the event needs a list of individuals to invite to the course.

- When a DLA official is planning to visit a specific location and wants to be aware of potential key pain points for the units located at the installation 

being visited.

REPORTING PERIOD TIME FRAME 

Start of Reporting Period: End of Reporting Period:

How often would you like to receive the report?

One-time

Monthly

Quarterly

Semi-annually

Annually

Other (Please explain):
No. 10-11157.

#### John McDowell, Petitioner v. Jerome W. Walsh, Superintendent, State Correctional Institution at Dallas, et al.

565 U.S. 1046, 132 S. Ct. 606,

181 L. Ed. 2d 444,

2011 U.S. LEXIS 8121.

November 14, 2011.

Petition for rehearing denied.

Former decision, 565 U.S. 870, 132 S. Ct. 222, 181 L. Ed. 2d 123, 2011 U.S. LEXIS 6577.
[Federal Register Volume 63, Number 135 (Wednesday, July 15, 1998)]
[Notices]
[Pages 38159-38160]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-18805]


-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission
[Docket No. RP98-340-000]


Mississippi River Transmission Corporation; Notice of Proposed 
Changes in FERC Gas Tariff

July 9, 1998.
    Take notice that on July 2, 1998, Mississippi River Transmission 
Corporation (MRT) tendered for filing as part of its FERC Gas Tariff, 
Third Revised Volume No. 1, the following revised tariff sheet to be 
effective August 1, 1998:


[[Page 38160]]


Fifth Revised Sheet No. 80

    In compliance with the Commission's April 16, 1998 Order No. 587-G 
in Docket No. RM96-1-007, MRT submits the referenced tariff sheet to 
incorporate by reference GISB Standards Version 1.2.
    Any person desiring to be heard or to protest this filing should 
file a motion to intervene or a protest with the Federal Energy 
Regulatory Commission, 888 First Street, N.E., Washington, D.C. 20426, 
in accordance with Sections 385.214 and 385.211 of the Commission's 
Rules and Regulations. All such motions or protests must be filed as 
provided in Section 154.210 of the Commission's Regulations. Protests 
will be considered by the Commission in determining the appropriate 
action to be taken, but will not serve to make protestants parties to 
the proceedings. Any person wishing to become a party must file a 
motion to intervene. Copies of this filing are on file with the 
Commission and are available for public inspection in the Public 
Reference Room.
David P. Boergers,
Acting Secretary.
[FR Doc. 98-18805 Filed 7-14-98; 8:45 am]
BILLING CODE 6717-01-M
* Pursuant to 5 TH C IR . R. 47.5, the court has determined

that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 00-20923 Summary Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus GUY WILLIAMS, Defendant-Appellant.

-------------------- Appeal from the United States District Court for the Southern District of Texas USDC No. H-00-CR-257-1

-------------------- June 19, 2001 Before SMITH, BENAVIDES, and DENNIS, Circuit Judges. PER CURIAM: * Court-appointed counsel representing Guy Williams has moved for leave to withdraw and has filed a brief in accordance with Anders v. California , 386 U.S. 738 (1967). Williams was provided with a copy of counsel’s Anders motion and brief. Williams has filed a response asserting that his sentence was improper in light of Apprendi v. New Jersey , 530 U.S. 466 (2000), and requesting the appointment of substitute counsel. Ou r independent review of the record, counsel’s brief, and Williams’ response shows that there are no nonfrivolous issuesNo. 00-20923 -2- for appeal. Consequently, Williams’ motion to substitute counsel is DENIED AS MOOT, counsel’s motion for leave to withdraw is GRANTED, counsel is excused from further responsibilities herein, and the APPEAL IS DISMISSED. See 5th Cir. R. 42.2.
CÓMO FORTALECEN LAS VACUNAS EL 

SISTEMA INMUNITARIO DE SU BEBÉ

Su hijo está expuesto a miles de microbios 

en su entorno todos los días. 

Esto sucede a través de los alimentos que 

come, el aire que respira y las cosas que se 

lleva a la boca.

Los bebés nacen con un sistema inmunitario 

que puede combatir la mayoría de los 

microbios, pero hay algunas enfermedades 

contra las que no pueden luchar. 

Por eso es que necesitan las vacunas para 

reforzar su sistema inmunitario.

Las vacunas usan cantidades muy pequeñas de 

antígenos para ayudar al sistema inmunitario de 

su hijo a reconocer y a aprender a combatir las 

enfermedades graves.

Los antígenos son partes de microbios que hacen 

que el sistema inmunitario del cuerpo se ponga 

en funcionamiento.

HACE 30 AÑOS

las vacunas usaban

antígenos

3000

para proteger contra

8

enfermedades

hasta los dos años

HOY

las vacunas usan

305

antígenos

para proteger contra

14

enfermedades

hasta los dos años

Gracias a los avances 

científicos, las vacunas 

de hoy en día pueden 

proteger a los niños contra 

más enfermedades usando 

menos antígenos.

Las vacunas solo contienen 

una fracción muy pequeñita 

de los antígenos que los bebés 

encuentran en su entorno 

cada día.

CON SALUD, 

TODO ES POSIBLE. 

VACUNE A SUS HIJOS.

Las vacunas ayudan a fortalecer 

el sistema inmunitario de su bebé 

y lo mantienen seguro contra las 

enfermedades prevenibles con vacunas.

U.S. Department of 

Health and Human Services 

Centers for Disease 

Control and Prevention 

www.cdc.gov/spanish/inmunizacion

NCIRDig603 | MLS - 285582 | 11/15/17
Exhibit 32.1 

CERTIFICATION 

        Theundersigned officer of DOV Pharmaceutical, Inc. (the “Company”) hereby certifiesthat the Company’s quarterly report on Form 10-Q to which this certification isattached (the “Report”), as filed with the Securities and Exchange Commission onthe date hereof, fully complies with the requirements of Section 13(a) or 15(d), asapplicable, of the Securities Exchange Act of 1934, as amended (the “ExchangeAct”), and that the information contained in the Report fairly presents, in allmaterial respects, the financial condition and results of operations of the Company. Thiscertification is provided solely pursuant to 18 U.S.C. Section 1350 and Item 601(b)(32) ofRegulation S-K (“Item 601(b)(32)”) promulgated under the Securities Act of 1933,as amended (the “Securities Act”), and the Exchange Act. In accordance withclause (ii) of Item 601(b)(32), this certification (A) shall not be deemed“filed” for purposes of Section 18 of the Exchange Act, or otherwise subject tothe liability of that section, and (B) shall not be deemed to be incorporated by referenceinto any filing under the Securities Act or the Exchange Act, except to the extent thatthe Company specifically incorporates it by reference. 

| Date: November 14, 2003 |   | By: |   | /s/  ARNOLD S. LIPPA      
Arnold S. Lippa    Chief Executive Officer and Secretary
38 |
|-------------------------|--------|-----|--------|--------------------------------------------------------------------------------------------------------------------------------|
No. 11-6874.

#### Pedro Michael Gon-calves, aka Mike Goncalves, Petitioner v. United States.

565 U.S. 1043, 132 S. Ct. 596,

181 L. Ed. 2d 437,

2011 U.S. LEXIS 8217.

November 14, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the First Circuit denied.

Same case below, 642 F.3d 245.
No. 11-6186.

#### Antoine Killing, Petitioner v. United States.

565 U.S. 956, 132 S. Ct. 433,

181 L. Ed. 2d 281,

2011 U.S. LEXIS 7240.

October 11, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Eighth Circuit denied.

Same case below, 417 Fed. Appx. 615.